We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Four Cancer Chemoprevention Trials Seek Subjects

Dec 1, 1996
Volume: 
5
Issue: 
12

MANHASSET, NY--High-risk individuals are being enrolled in four
multicenter clinical trials aimed at preventing lung, breast,
colorectal and prostate cancers. These cancers together account
for more than half of all cancer deaths, Laura Donahue, MD, said
as she recruited participants at North Shore University Hospital's
Don Monti Cancer Center Screening and Education Day.

The National Cancer Institute (NCI) is funding these double-blind,
placebo-controlled prospective trials, which will be conducted
in collaboration with hundreds of hospitals and medical centers
in the United States and Canada.

Patients who had stage I non-small-cell lung cancer with no more
than one primary tumor at a time are eligible to enter the Lung
Cancer Prevention Trial if they underwent complete surgical resection
within the past 3 years and are no longer receiving cancer therapy.

"Despite the early stage of diagnosis, 5-year survival is
still poor in this population, ranging between 50% and 60%, Dr.
Donahue said. Moreover, she added, in long-term survivors of the
initial surgery, the incidence of second primary tumors can range
up to 12%.

More than 1,000 patients will be randomized to receive either
30 mg of 13-cis-retinoic acid or a placebo daily for 3 years,
with 4-year follow-up.

Retinoids have been shown to halt the progress of premalignant
lesions of the oral cavity, cervix, and skin, Dr. Donahue noted,
and to prevent second primary tumors in head, neck, and lung cancer
patients. This trial will assess the qualitative and quantitative
toxicity of daily use.

The Breast Cancer Prevention Trial will examine whether tamoxifen
(Nol-vadex) can reduce the incidence of and mortality from breast
cancer in 13,000 healthy women considered at high risk, based
on an NCI model. This study was undertaken because tamoxifen has
proven effective in preventing recurrent disease in breast cancer
patients.

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.